Lohnt der Einstieg bei Novo Nordisk und BIP-Champion Hamburg
Der Börsen-Podcast Außerdem geht es um Merck & Co, Amgen, Johnson&Johnson, Gold, AstraZeneca, ON Semiconductor, DoorDash, Grail, MongoDB, PayPal, NXP Semiconductors, Alphabet, Strategy, Lululemon, Vonovia, TAG Immobilien, Grand City Properties, Patrizia, Hapag-Lloyd, Beiersdorf, Airbus, Biontech, BASF, Eli Lilly und…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Alles auf Aktien – Die täglichen Finanzen-News
See all episodes →
Kapitalismus-Crash, Cash, AOC-Begegnung – Angermayer packt aus
Die verheißungsvolle Lateinamerika-Wette und der Edelmetall-Check
Börsenalarm der Elite-Ökonomen und der GmbH-Trick beim Neobroker
Similar episodes from other shows
More like Alles auf Aktien – Die täglichen Finanzen-News →
In Sachen Bulle: 15 Lieblingsaktien der Handelsblatt-Redaktion
Rendite-Contest: AT&T, Verizon und T-Mobile US im Vergleich (Express)
Novo Nordisk hits back at copycat drugs
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.